Physician profile
Omar Ayala
NPI 1952573867
$1,091.49
in general payments reported to CMS, 2019-2025
19 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.35 · 2021: $79.33 · 2022: $65.57 · 2023: $158 · 2024: $477 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.66 | 2022-2025 | Vraylar |
| Neuronetics, INC. | $208.61 | 2023-2024 | Neurostar Tms Therapy System |
| Corium, LLC | $114.77 | 2022-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $99.67 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $76.49 | 2022-2025 | Abilify Mycite, Rexulti |
| Sunovion Pharmaceuticals INC. | $54.89 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.99 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $48.64 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $41.82 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $36.91 | 2025 | Fanapt |
| Tris Pharma INC | $31.65 | 2022-2025 | Onyda Xr |
| Avion Pharmaceuticals | $18.28 | 2023 | Methylphenidate Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $16.98 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $15.86 | 2023 | Quviviq |
| Neos Therapeutics, LP | $14.79 | 2024 | Cotempla Xr-Odt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.86 | 2024 | Rexulti |
| Owp Pharmaceuticals, INC. | $13.68 | 2024 | Subvenite |
| Janssen Pharmaceuticals, INC | $13.48 | 2021 | |
| Shire North American Group INC | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.